Department of Chemistry and Research institute of Natural sciences, Hanyang University, Seoul 133-791, South Korea.
Enzyme Microb Technol. 2011 Jun 10;49(1):1-5. doi: 10.1016/j.enzmictec.2011.04.004. Epub 2011 Apr 8.
Acetohydroxyacid synthase (AHAS), a potential target for antimicrobial agents, catalyzes the first common step in the biosynthesis of branched-chain amino acids. The gene coding for the AHAS catalytic subunit from Haemophilus influenzae (Hi) was cloned, overexpressed in Escherichia coli, and purified. To identify new inhibitory scaffolds, we used a high-throughput screen to test 221 small diverse chemical compounds against Hi-AHAS. Compounds were selected for their ability to inhibit AHAS in vitro. The screen identified 3 compounds, each representing a structural class, as Hi-AHAS inhibitors with an IC(50) in the low micromolar range (4.4-14.6 μM). The chemical scaffolds of the three compounds were oxa-1-thia-4-aza-cyclopenta[b]naphthalene (KHG25229), phenyl-2,3-dihydro-isothiazole (KHG25386), and phenyl-pyrrolidine-3-carboxylic acid phenylamide (KHG25056). Further, molecular docking of the two most potent chemicals, KHG25229 and KHG25386, in Hi-AHAS yielded binding energies of -10.41 and -9.21 kcal/mol, respectively. The binding modes were consistent with inhibition mechanisms, as both chemicals oriented outside the active site. As the need for novel antibiotic classes to combat drug resistant bacteria increases, screening compounds that act against Hi-AHAS may assist in the identification of potential new anti-Hi drugs.
乙酰羟酸合酶(AHAS)是抗菌药物的潜在靶标,催化支链氨基酸生物合成的第一个共同步骤。从流感嗜血杆菌(Hi)克隆编码 AHAS 催化亚基的基因,在大肠杆菌中过表达并纯化。为了鉴定新的抑制骨架,我们使用高通量筛选测试了 221 种不同的小分子化合物对 Hi-AHAS 的抑制作用。选择化合物是基于它们在体外抑制 AHAS 的能力。筛选鉴定了 3 种化合物,每种化合物都代表一个结构类别,是具有低微摩尔范围(4.4-14.6 μM)IC50 的 Hi-AHAS 抑制剂。这三种化合物的化学骨架分别为氧杂-1-硫杂-4-氮杂环戊[b]萘(KHG25229)、苯基-2,3-二氢-异噻唑(KHG25386)和苯基-吡咯烷-3-羧酸苯酰胺(KHG25056)。此外,将两种最有效的化合物 KHG25229 和 KHG25386 在 Hi-AHAS 中的分子对接产生的结合能分别为-10.41 和-9.21 kcal/mol。结合模式与抑制机制一致,因为这两种化学物质都定向在活性位点之外。随着对抗耐药菌的新型抗生素类别的需求增加,筛选针对 Hi-AHAS 的化合物可能有助于鉴定潜在的新型抗 Hi 药物。